Researchers at Baylor College of Medicine discovered that the use of drug Zotatifin to target protein elF4A in testing on triple-negative breast cancer (TNBC) animal models suppressed tumour growth and improved the immune microenvironment of the tumour. These findings indicate a potential new avenue for TNBC treatment, with the possibility of clinical trials to assess patient benefits.
DaVita ransomware attack impacts 2.7M individuals – TechTarget
DaVita ransomware attack impacts 2.7M individuals TechTarget
